tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
TuHURA Biosciences Increases Authorized Common Stock Shares
PremiumCompany AnnouncementsTuHURA Biosciences Increases Authorized Common Stock Shares
2M ago
Buy Rating for TuHURA Biosciences: Promising Phase 3 Study and Strategic Merger with Kineta Inc.
Premium
Ratings
Buy Rating for TuHURA Biosciences: Promising Phase 3 Study and Strategic Merger with Kineta Inc.
3M ago
TuHURA Biosciences initiates Phase 3 approval trial of IFx-2.0 in carcinoma
Premium
The Fly
TuHURA Biosciences initiates Phase 3 approval trial of IFx-2.0 in carcinoma
3M ago
TuHURA announces FDA removed partial clinical hold on Phase 3 trial of IFx-2.0
PremiumThe FlyTuHURA announces FDA removed partial clinical hold on Phase 3 trial of IFx-2.0
3M ago
TuHURA Biosciences Secures $12.6M for Strategic Initiatives
Premium
Company Announcements
TuHURA Biosciences Secures $12.6M for Strategic Initiatives
3M ago
TuHURA Biosciences: Promising Oncology Advancements and Strategic Acquisitions Drive Buy Rating
Premium
Ratings
TuHURA Biosciences: Promising Oncology Advancements and Strategic Acquisitions Drive Buy Rating
3M ago
TuHURA Biosciences initiates Phase 1b/2a study of IFx-Hu2.0 in carcinoma
PremiumThe FlyTuHURA Biosciences initiates Phase 1b/2a study of IFx-Hu2.0 in carcinoma
4M ago
TuHURA Biosciences: Promising Developments in Anti-VISTA Antibody and DNA-based Immune Activator Justify Buy Rating
Premium
Ratings
TuHURA Biosciences: Promising Developments in Anti-VISTA Antibody and DNA-based Immune Activator Justify Buy Rating
4M ago
TuHURA Biosciences and Kineta present updated results of cancer candidates
Premium
The Fly
TuHURA Biosciences and Kineta present updated results of cancer candidates
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100